Mechanistically, DUSP4 deficiency activated the MAPK/ERK pathway, while inhibition of ERK enhanced treatment sensitivity to Lenvatinib in KO-DUSP4 HCC cells. Here, DUSP4 is linked to hepatocellular carcinoma.